| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562258162P | 2015-11-20 | 2015-11-20 | |
| PCT/US2016/062837WO2017087837A1 (en) | 2015-11-20 | 2016-11-18 | Purinones as ubiquitin-specific protease 1 inhibitors |
| Publication Number | Publication Date |
|---|---|
| SG11201804098TAtrue SG11201804098TA (en) | 2018-06-28 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804098TASG11201804098TA (en) | 2015-11-20 | 2016-11-18 | Purinones as ubiquitin-specific protease 1 inhibitors |
| Country | Link |
|---|---|
| US (4) | US10189841B2 (en) |
| EP (2) | EP3696181A1 (en) |
| JP (3) | JP6964343B2 (en) |
| KR (1) | KR102708936B1 (en) |
| CN (2) | CN114702495A (en) |
| AU (3) | AU2016356694B2 (en) |
| BR (1) | BR112018010216B1 (en) |
| CA (1) | CA3005353A1 (en) |
| IL (3) | IL300788A (en) |
| MX (2) | MX2021001186A (en) |
| RU (1) | RU2750151C2 (en) |
| SG (1) | SG11201804098TA (en) |
| WO (1) | WO2017087837A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021001186A (en) | 2015-11-20 | 2022-10-11 | Forma Therapeutics Inc | Purinones as ubiquitin-specific protease 1 inhibitors. |
| EP3703669B1 (en) | 2017-11-01 | 2025-08-06 | Dana-Farber Cancer Institute, Inc. | Usp1 or uaf1 inhibitors for use in treating cancer |
| WO2019189731A1 (en) | 2018-03-30 | 2019-10-03 | 住友化学株式会社 | Heterocyclic compound and arthropod pest control composition containing same |
| KR102316234B1 (en) | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 1,3,4-Oxadiazole Derivative Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same |
| MA53275A (en)* | 2018-08-09 | 2021-09-15 | Valo Early Discovery Inc | CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS |
| CN109503421B (en)* | 2018-11-20 | 2022-10-14 | 黎明化工研究设计院有限责任公司 | Method for improving safety of azide amine fuel synthesis process |
| AU2019405925B2 (en)* | 2018-12-20 | 2025-07-03 | KSQ Therapeutics, Inc. | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors |
| WO2020139988A1 (en)* | 2018-12-28 | 2020-07-02 | Forma Therapeutics, Inc. | Compositions for inhibiting ubiquitin specific protease 1 |
| WO2020240493A1 (en)* | 2019-05-31 | 2020-12-03 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole homophthalimide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| CA3139026A1 (en)* | 2019-05-31 | 2020-12-03 | Chang Sik Lee | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
| CN110759902B (en)* | 2019-11-01 | 2022-04-22 | 海南一龄医疗产业发展有限公司 | SET8 lysine methyltransferase inhibitor and preparation method and application thereof |
| US20230183215A1 (en)* | 2020-05-21 | 2023-06-15 | Stemsynergy Therapeutics, Inc. | Notch Inhibitors and Uses Thereof |
| EP4161494A4 (en)* | 2020-06-02 | 2024-07-17 | KSQ Therapeutics, Inc. | NITROGEN-CONTAINING CONDENSED BICYCLIC COMPOUNDS AND THEIR USE AS UBIQUITIN-SPECIFIC PROCESSING PROTEASE 1 (USP1) INHIBITORS |
| KR102458689B1 (en)* | 2020-07-08 | 2022-10-25 | 원광대학교산학협력단 | Piperidine compound and method for producing the same |
| KR102685058B1 (en)* | 2020-09-02 | 2024-07-15 | 주식회사 종근당 | Novel Compounds as Histone Deacetylase 6 Inhibitor, and the Pharmaceutical Composition Comprising the same |
| CN111926018B (en)* | 2020-09-04 | 2022-07-12 | 首都医科大学附属北京儿童医院 | Application of substance for reducing USP1 expression in preparation of medicine for treating children T-line acute lymphoblastic leukemia |
| MX2023004937A (en) | 2020-10-30 | 2023-05-17 | Ksq Therapeutics Inc | Solid state forms of substituted pyrazolopyrimidines and uses thereof. |
| WO2022197892A1 (en)* | 2021-03-17 | 2022-09-22 | Tango Therapeutics, Inc. | Purine derivatives as anticancer agents |
| WO2022199547A1 (en)* | 2021-03-22 | 2022-09-29 | 成都赜灵生物医药科技有限公司 | 7,9-dihydropurine derivative and pharmaceutical purpose thereof |
| CA3214040A1 (en)* | 2021-04-07 | 2022-10-13 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 1 (usp1) |
| US20240226107A1 (en)* | 2021-04-09 | 2024-07-11 | Simcere Zaiming Pharmaceutical Co., Ltd. | Ubiquitin-specific protease 1 (usp1) inhibitor |
| WO2023069959A1 (en)* | 2021-10-18 | 2023-04-27 | Dana-Farber Cancer Institute, Inc. | Covalent egfr inhibitors and methods of use thereof |
| EP4429770A1 (en)* | 2021-11-10 | 2024-09-18 | Biogen MA Inc. | Btk inhibitors |
| TW202327602A (en)* | 2021-11-12 | 2023-07-16 | 香港商英科智能有限公司 | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
| EP4430050A4 (en)* | 2021-11-12 | 2025-09-24 | Insilico Medicine Ip Ltd | Small molecule inhibitors of ubiquitin-specific protease 1 (USP1) and uses thereof |
| JP2024543497A (en)* | 2021-11-12 | 2024-11-21 | インシリコ メディシン アイピー リミテッド | Small molecule inhibitors of ubiquitin-specific protease 1 (USP1) and uses thereof |
| EP4472946A1 (en)* | 2022-02-03 | 2024-12-11 | Exelixis, Inc. | Fused bicyclic heterocyclyl compounds as usp1 inhibitors |
| EP4516779A1 (en)* | 2022-04-29 | 2025-03-05 | Jiangsu Yahong Meditech Co., Ltd. | Pyrimidine compound, method for preparing same, and pharmaceutical use thereof |
| CN119731178A (en)* | 2022-06-23 | 2025-03-28 | 福马治疗有限公司 | USP1 inhibitors and uses thereof |
| US20240092779A1 (en)* | 2022-06-29 | 2024-03-21 | Zentaur Therapeutics Usa Inc. | Usp1 inhibitors and uses thereof |
| WO2024022266A1 (en)* | 2022-07-25 | 2024-02-01 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heteroaryl compounds as inhibitors of usp1 |
| WO2024022519A1 (en)* | 2022-07-28 | 2024-02-01 | 先声再明医药有限公司 | Heterocycle fused pyrimidine compound and use thereof |
| WO2024041634A1 (en)* | 2022-08-26 | 2024-02-29 | 先声再明医药有限公司 | Tricyclic compound and use thereof |
| CN119698417A (en)* | 2022-09-09 | 2025-03-25 | 正大天晴药业集团股份有限公司 | Substituted purinone derivatives as ubiquitin-specific protease inhibitors |
| IL319492A (en)* | 2022-09-20 | 2025-05-01 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Carbonyl fused heterocyclic derivative used as ubiquitin-specific protease inhibitor |
| CN120092007A (en)* | 2022-10-09 | 2025-06-03 | 海南先声再明医药股份有限公司 | Heterocyclic pyrimidine compounds, pharmaceutical compositions and applications thereof |
| EP4605391A1 (en) | 2022-10-21 | 2025-08-27 | Exelixis, Inc. | 4,5,6,7-tetrahydro-1-pyrazolo[4,3-c]pyridine compounds and derivatives as usp1 inhibitors |
| WO2024153175A1 (en) | 2023-01-19 | 2024-07-25 | Laekna Therapeutics Shanghai Co., Ltd. | Heteroaromatic compounds and their use as usp1 inhibitors |
| TW202509030A (en) | 2023-05-08 | 2025-03-01 | 美商譚格醫療公司 | Compounds and methods of use |
| WO2024233665A1 (en) | 2023-05-08 | 2024-11-14 | Tango Therapeutics, Inc. | Compounds and their use against cancer |
| WO2025010245A1 (en) | 2023-07-06 | 2025-01-09 | Exelixis, Inc. | Fused pyrazole derivatives as usp1 inhibitors |
| CN116621846B (en)* | 2023-07-24 | 2023-10-17 | 华润医药研究院(深圳)有限公司 | Bicyclic heterocycle and tricyclic heterocycle compounds, and preparation method and medical application thereof |
| WO2025067259A1 (en)* | 2023-09-26 | 2025-04-03 | 上海济煜医药科技有限公司 | Preparation method for nitrogen heterocyclic amine compound which acts as ubiquitin-specific protease 1 inhibitor, and application and use |
| WO2025102016A1 (en) | 2023-11-10 | 2025-05-15 | Vrise Therapeutics, Inc. | Novel molecules as inhibitors of dna damage repair pathway |
| WO2025151705A1 (en) | 2024-01-10 | 2025-07-17 | Vrise Therapeutics, Inc. | Novel inhibitors of dna damage repair pathway |
| CN119707772B (en)* | 2024-12-23 | 2025-09-02 | 浙江大学 | A USP14 covalent inhibitor and its preparation method and application |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440929A (en) | 1981-07-16 | 1984-04-03 | Usv Pharmaceutical Corporation | Imidazoquinoxaline compounds |
| DK476885D0 (en) | 1985-10-17 | 1985-10-17 | Ferrosan As | HETEROCYCLIC RELATIONS AND PROCEDURES FOR PREPARING IT |
| US4859672A (en) | 1986-10-29 | 1989-08-22 | Rorer Pharmaceutical Corporation | Pyrido[2,3-d]pyrimidinone and imidazo[4,5-b]pyrimidinone |
| JPS63199347A (en) | 1987-02-14 | 1988-08-17 | Konica Corp | High-sensitivity silver halide photographic sensitive material having improved sharpness |
| IL90315A0 (en) | 1988-06-01 | 1989-12-15 | Ferrosan As | Imidazoquinoxaline compounds,their preparation and pharmaceutical compositions containing them |
| DK626288D0 (en) | 1988-11-10 | 1988-11-10 | Ferrosan As | CHEMICAL PROCESS FOR THE PREPARATION OF IMIDAZOQUINOXALINES AND INTERMEDIATES FOR USE IN THE PROCESS |
| FR2643903A1 (en) | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | NOVEL BENZIMIDAZOLE DERIVATIVES, PROCESSES FOR PREPARING SAME, SYNTHESIS INTERMEDIATES, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, IN PARTICULAR FOR THE TREATMENT OF CARDIOVASCULAR DISEASES, AND DUODENIAL ULCERS |
| DK588489D0 (en) | 1989-11-22 | 1989-11-22 | Ferrosan As | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND USE |
| CA2110942A1 (en) | 1991-06-14 | 1992-12-23 | Pharmacia & Upjohn Company Llc | Imidazo¬1,5-a|quinoxalines |
| AU4035893A (en) | 1991-12-17 | 1993-07-19 | Upjohn Company, The | 3-substituted imidazo (1,5-a) and imidazo (1,5-a)-triazolo (1,5-c) quinoxalines and quinazolines with cns activity |
| EP0626966A1 (en) | 1992-02-19 | 1994-12-07 | PHARMACIA & UPJOHN COMPANY | 3-substituted imidazo(1,5-a)quinoxalines and quinazolines with cns activity |
| US6444656B1 (en) | 1992-12-23 | 2002-09-03 | Biochem Pharma, Inc. | Antiviral phosphonate nucleotides |
| GB9226879D0 (en) | 1992-12-23 | 1993-02-17 | Iaf Biochem Int | Anti-viral compounds |
| US5516774A (en) | 1993-07-29 | 1996-05-14 | American Cyanamid Company | Tricyclic diazepine vasopressin antagonists and oxytocin antagonists |
| US5521173A (en) | 1995-01-17 | 1996-05-28 | American Home Products Corporation | Tricyclic benzazepine vasopressin antagonists |
| ZA973884B (en) | 1996-05-23 | 1998-11-06 | Du Pont Merck Pharma | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders |
| EP1043324B1 (en) | 1997-11-12 | 2004-06-16 | Mitsubishi Chemical Corporation | Purine derivatives and medicine containing the same as the active ingredient |
| ZA9810490B (en) | 1997-12-03 | 1999-05-20 | Dainippon Pharmaceutical Co | 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor |
| TW572758B (en)* | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
| CZ27399A3 (en) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituted nitrogen heterocyclic derivatives process of their preparation, the derivatives employed as medicaments, pharmaceutical composition and a compound pharmaceutical preparation in which these derivatives are comprised as well as use of these derivatives for preparing medicaments |
| JP3814125B2 (en) | 1999-06-02 | 2006-08-23 | 大日本住友製薬株式会社 | Pharmaceutical comprising 2-aryl-8-oxodihydropurine derivative |
| WO2001049688A1 (en) | 2000-01-07 | 2001-07-12 | Universitaire Instelling Antwerpen | Purine derivatives, process for their preparation and use thereof |
| JP3675274B2 (en) | 2000-01-27 | 2005-07-27 | ダイソー株式会社 | Method for producing 9- (2-hydroxyalkyl) purine derivative and 1- (2-hydroxyalkyl) pyrimidine derivative |
| US20020128264A1 (en) | 2000-07-07 | 2002-09-12 | Taylor Eve M. | Methods for treatment of conditions affected by activity of multidrug transporters |
| EP1334104A2 (en) | 2000-07-07 | 2003-08-13 | Neotherapeutics, Inc. | Methods for treatment of drug-induced peripheral neuropathy and related conditions |
| US20020040031A1 (en) | 2000-07-07 | 2002-04-04 | Glasky Michelle S. | Methods for prevention of accumulation of amyloid beta peptide in the central nervous system |
| US20020040032A1 (en) | 2000-07-07 | 2002-04-04 | Glasky Michelle S. | Methods for stimulation of synthesis of synaptophysin in the central nervous system |
| WO2002058736A2 (en) | 2000-12-12 | 2002-08-01 | Neotherapetics, Inc. | Use of 9-substituted purine analogues and other molecules to stimulate neurogenesis |
| US6960595B2 (en) | 2001-03-23 | 2005-11-01 | Bristol-Myers Squibb Pharma Company | 5-6 to 5-7 Heterobicycles as factor Xa inhibitors |
| US20020156277A1 (en) | 2001-04-20 | 2002-10-24 | Fick David B. | Synthesis and methods of use of purine analogues and derivatives |
| JPWO2003068776A1 (en) | 2002-02-15 | 2005-06-02 | 協和醗酵工業株式会社 | [1,2,4] Triazolo [1,5-c] pyrimidine derivatives |
| CA2477741A1 (en) | 2002-02-28 | 2003-09-04 | Biota, Inc. | Nucleotide mimics and their prodrugs |
| US7247621B2 (en) | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
| ES2270143T3 (en) | 2002-08-07 | 2007-04-01 | Novartis Ag | ORGANIC COMPOUNDS AS AGENTS FOR THE TREATMENT OF CONDITIONS MEDIATED BY ALDOSTERONE. |
| US7371857B2 (en) | 2002-08-08 | 2008-05-13 | Valeant Research & Development | Synthesis for hydroxyalkylated heterocyclic bases |
| US20040166137A1 (en) | 2002-11-08 | 2004-08-26 | Lackey John William | Hetero-substituted benzimidazole compounds and antiviral uses thereof |
| JP2004217582A (en) | 2003-01-16 | 2004-08-05 | Abbott Japan Co Ltd | 9H-purine derivative |
| US20040180898A1 (en) | 2003-03-03 | 2004-09-16 | Bang-Chi Chen | Processes for preparing imidazoquinoxalinones, heterocyclic-substituted imidazopyrazinones, imidazoquinoxalines and heterocyclic-substituted imidazopyrazines |
| AU2004255585A1 (en) | 2003-07-02 | 2005-01-20 | F. Hoffmann-La Roche Ag | 5-substituted quinazolinone derivatives |
| AU2004259736A1 (en) | 2003-07-23 | 2005-02-03 | Wyeth | Sulfonyldihydroimid- azopyridinone compounds as 5-hydroxytryptamine-6 ligands |
| US20050043239A1 (en) | 2003-08-14 | 2005-02-24 | Jason Douangpanya | Methods of inhibiting immune responses stimulated by an endogenous factor |
| WO2005016349A1 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Methods of inhibiting leukocyte accumulation |
| CA2552664A1 (en) | 2004-01-08 | 2005-07-28 | Michigan State University | Methods for treating and preventing hypertension and hypertension-related disorders |
| AU2005214380A1 (en) | 2004-02-18 | 2005-09-01 | Astrazeneca Ab | Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders |
| CA2566436C (en) | 2004-05-13 | 2011-05-10 | Vanderbilt University | Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
| CA2567883A1 (en) | 2004-05-25 | 2005-12-15 | Icos Corporation | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells |
| CA2569406A1 (en) | 2004-06-04 | 2005-12-22 | Icos Corporation | Methods for treating mast cell disorders |
| WO2006044504A1 (en) | 2004-10-13 | 2006-04-27 | Merck & Co., Inc. | Cgrp receptor antagonists |
| WO2006084281A1 (en) | 2005-02-04 | 2006-08-10 | Millennium Pharmaceuticals, Inc. | Inhibitors of e1 activating enzymes |
| US20080287469A1 (en) | 2005-02-17 | 2008-11-20 | Diacovo Thomas G | Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation |
| US7884109B2 (en) | 2005-04-05 | 2011-02-08 | Wyeth Llc | Purine and imidazopyridine derivatives for immunosuppression |
| US20070021443A1 (en) | 2005-04-05 | 2007-01-25 | Ohlmeyer Michael J | Purine and imidazopyridine derivatives for immunosuppression |
| US20090023723A1 (en) | 2005-09-21 | 2009-01-22 | Pharmacopeia Drug Discovery, Inc. | Purinone derivatives for treating neurodegenerative diseases |
| DE102005062987A1 (en) | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituted propiolic acid amides and their use for the preparation of medicaments |
| US7989459B2 (en) | 2006-02-17 | 2011-08-02 | Pharmacopeia, Llc | Purinones and 1H-imidazopyridinones as PKC-theta inhibitors |
| AU2007267793A1 (en) | 2006-05-26 | 2007-12-06 | Novartis Ag | Aldosterone synthase and/or 11beta-hydroxylase inhibitors |
| TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| WO2007149484A2 (en) | 2006-06-20 | 2007-12-27 | Dana-Farber Cancer Institute | Inhibitors of usp1 deubiquitinating enzyme complex |
| US20100144738A1 (en)* | 2006-09-05 | 2010-06-10 | William Bornmann | Inhibitors of c-met and uses thereof |
| JP5600004B2 (en)* | 2006-09-05 | 2014-10-01 | エモリー ユニバーシティー | Tyrosine kinase inhibitors for the prevention or treatment of infection |
| WO2008045529A1 (en) | 2006-10-12 | 2008-04-17 | Serenex, Inc. | Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases |
| CA2666624C (en)* | 2006-10-19 | 2015-12-29 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
| US20080119496A1 (en) | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
| AU2006350748A1 (en) | 2006-11-16 | 2008-05-22 | Pharmacopeia, Llc | 7-substituted purine derivatives for immunosuppression |
| US7943617B2 (en) | 2006-11-27 | 2011-05-17 | Bristol-Myers Squibb Company | Heterobicyclic compounds useful as kinase inhibitors |
| AR065784A1 (en) | 2007-03-20 | 2009-07-01 | Dainippon Sumitomo Pharma Co | DERIVATIVES OF 8-OXO ADENINE, DRUGS THAT CONTAIN THEM AND USES AS THERAPEUTIC AGENTS FOR ALLERGIC, ANTIVIRAL OR ANTIBACTERIAL DISEASES. |
| JP2010522177A (en) | 2007-03-23 | 2010-07-01 | アムジエン・インコーポレーテツド | Heterocyclic compounds and uses thereof |
| WO2008117796A1 (en) | 2007-03-28 | 2008-10-02 | Dainippon Sumitomo Pharma Co., Ltd. | Novel mutilin derivatives |
| US20090182035A1 (en) | 2007-04-11 | 2009-07-16 | Alcon Research, Ltd. | Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis |
| MX2009010946A (en) | 2007-04-11 | 2009-10-29 | Alcon Res Ltd | Use of an inhibitor of tnfa plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis. |
| WO2008131501A2 (en) | 2007-04-27 | 2008-11-06 | Katholieke Universiteit Leuven | New anti-viral nucleoside analogs |
| GB0708258D0 (en) | 2007-04-27 | 2007-06-06 | Katholleke Universiteit Leuven | New anti-viral nulceoside analogs |
| WO2008143674A1 (en) | 2007-05-23 | 2008-11-27 | Pharmacopeia, Inc. | Purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
| CA2691857A1 (en) | 2007-06-26 | 2008-12-31 | Jorge Alonso | A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles |
| JP2009007273A (en) | 2007-06-27 | 2009-01-15 | Ajinomoto Co Inc | Method for producing diaminopyrimidine compound |
| US20090118301A1 (en) | 2007-11-02 | 2009-05-07 | Arbor Vita Corporation | Compositions and Methods for Treating Cancer |
| WO2009062059A2 (en) | 2007-11-08 | 2009-05-14 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
| EP2222661B1 (en) | 2007-11-20 | 2016-04-20 | Merck Sharp & Dohme Corp. | Non-nucleoside reverse transcriptase inhibitors |
| JP2011505366A (en) | 2007-11-30 | 2011-02-24 | ワイス・エルエルシー | Aryl and heteroaryl fused imidazo [1,5-a] pyrazines as inhibitors of phosphoesterase 10 |
| WO2009068246A2 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of treating obesity and metabolic disorders |
| WO2009068320A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
| JP2011509961A (en) | 2008-01-17 | 2011-03-31 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Substituted sulfonamide derivatives |
| EP2229394A1 (en) | 2008-01-17 | 2010-09-22 | Grünenthal GmbH | Substituted sulfonamide derivatives |
| EP2085398A1 (en) | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| EP2090576A1 (en) | 2008-02-01 | 2009-08-19 | Merz Pharma GmbH & Co.KGaA | 6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators |
| EP2268280B1 (en) | 2008-03-21 | 2013-04-24 | Merck Sharp & Dohme Corp. | Quinolizidinone M1 receptor positive allosteric modulators |
| CA2722308C (en) | 2008-04-15 | 2024-02-27 | Rfs Pharma, Llc. | Nucleoside derivatives for treatment of caliciviridae infections, including norovirus infections |
| WO2009137462A2 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
| CN102131810B (en) | 2008-06-25 | 2014-02-26 | 百时美施贵宝公司 | Diketone fused azolopiperidines and azolopiperazines as anti-HIV agents |
| CA2736522C (en) | 2008-09-09 | 2016-09-13 | Boehringer Ingelheim International Gmbh | Aza-benzimidazolone chymase inhibitors |
| BRPI0918602B8 (en) | 2008-09-16 | 2021-05-25 | Benevolentai Cambridge Ltd | health activity inhibitors, their use, and pharmaceutical formulation |
| CA2738429C (en) | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
| US8835422B2 (en) | 2008-12-11 | 2014-09-16 | Cara Therapeutics, Inc. | Substituted imidazoheterocycle derivatives |
| CN101824036A (en) | 2009-03-05 | 2010-09-08 | 上海恒瑞医药有限公司 | Salt of tetrahydroimidazo [1,5-a] pyrazine derivative, preparation method and pharmaceutical application thereof |
| KR101675614B1 (en) | 2009-10-29 | 2016-11-11 | 벡투라 리미티드 | N-containing heteroaryl derivatives as jak3 kinase inhibitors |
| JP2011136925A (en) | 2009-12-28 | 2011-07-14 | Dainippon Sumitomo Pharma Co Ltd | Nitrogen-containing bicyclic compound |
| UA110697C2 (en) | 2010-02-03 | 2016-02-10 | Сігнал Фармасьютікалз, Елелсі | USE OF TOR KINASE INHIBITORS FOR TREATMENT OF TUMOR DISEASES IN A PATIENT WITH A REDUCED PAMPK PROTEIN AND / OR AMPK ACTIVITY |
| WO2011137320A2 (en) | 2010-04-30 | 2011-11-03 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibitors of usp1 deubiquitinating enzyme activity |
| WO2011156889A1 (en) | 2010-06-14 | 2011-12-22 | Trt Pharma Inc. | Novel modulators of nrf2 and uses thereof |
| EP2397482A1 (en) | 2010-06-15 | 2011-12-21 | Almirall, S.A. | Heteroaryl imidazolone derivatives as jak inhibitors |
| JP2012012332A (en) | 2010-06-30 | 2012-01-19 | Dainippon Sumitomo Pharma Co Ltd | New azaindole derivative |
| WO2012003576A1 (en) | 2010-07-06 | 2012-01-12 | Université de Montréal | Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators |
| WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
| CN102372716A (en) | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | Phthalazone derivative, its preparation method and application in medicine thereof |
| DE102010040233A1 (en) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic aza heterocycles and their use |
| CN102485721B (en) | 2010-12-03 | 2015-12-09 | 曹亚 | 2,3-benzodiazine ketone compound replaced and uses thereof |
| TWI515187B (en) | 2010-12-16 | 2016-01-01 | 健生科學愛爾蘭無限公司 | Indoles as respiratory syncytial virus antiviral agents |
| TWI501967B (en) | 2010-12-16 | 2015-10-01 | Janssen R&D Ireland | Azaindoles as respiratory syncytial virus antiviral agents |
| TWI527814B (en) | 2010-12-16 | 2016-04-01 | 健生科學愛爾蘭無限公司 | Azabenzimidazoles as respiratory syncytial virus antiviral agents |
| TWI541241B (en) | 2010-12-16 | 2016-07-11 | 健生科學愛爾蘭無限公司 | Imidazopyridines as respiratory syncytial virus antiviral agents |
| WO2012102405A1 (en) | 2011-01-28 | 2012-08-02 | 佐藤製薬株式会社 | Ring-fused compound |
| WO2012114252A1 (en) | 2011-02-21 | 2012-08-30 | Actelion Pharmaceuticals Ltd | Novel indole and pyrrolopyridine amides |
| CN105748484A (en) | 2011-03-26 | 2016-07-13 | 福拉姆医药股份有限公司 | Methods of targeted treatment of frontotemporal lobar degeneration |
| WO2012136492A1 (en) | 2011-04-04 | 2012-10-11 | Siena Biotech S.P.A. | Wnt pathway antagonists |
| WO2013025628A1 (en) | 2011-08-15 | 2013-02-21 | Ligand Pharmaceuticals Incorporated | Janus kinase inhibitor compounds and methods |
| WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
| IN2014CN02806A (en) | 2011-10-14 | 2015-07-03 | Bristol Myers Squibb Co | |
| JP2014530861A (en) | 2011-10-19 | 2014-11-20 | シグナル ファーマシューティカルズ,エルエルシー | Treatment of cancer with a TOR kinase inhibitor |
| US8501724B1 (en) | 2012-01-31 | 2013-08-06 | Pharmacyclics, Inc. | Purinone compounds as kinase inhibitors |
| EP2817029B1 (en) | 2012-02-24 | 2019-07-10 | Signal Pharmaceuticals, LLC | Methods for treating non-small cell lung cancer using tor kinase inhibitor combination therapy |
| WO2013134079A1 (en) | 2012-03-05 | 2013-09-12 | Amgen Inc. | Oxazolidinone compounds and derivatives thereof |
| US9338896B2 (en) | 2012-07-25 | 2016-05-10 | Enthone, Inc. | Adhesion promotion in printed circuit boards |
| US9566310B2 (en) | 2012-09-10 | 2017-02-14 | Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno | Methods of treating muscular dystrophy |
| WO2014043246A1 (en) | 2012-09-11 | 2014-03-20 | The Board Of Trustees Of The University Of Illinois | Enoyl reductase inhibitors with antibacterial activity |
| AU2013202768B2 (en)* | 2012-10-18 | 2015-11-05 | Signal Pharmaceuticals, Llc | Treatment of cancer with TOR kinase inhibitors |
| AU2013370417A1 (en) | 2012-12-28 | 2015-07-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof |
| JP6024979B2 (en) | 2013-02-21 | 2016-11-16 | 学校法人金沢工業大学 | Flame retardant composition, flame retardant treatment method and flame retardant material using the same |
| CN103923085B (en) | 2013-02-25 | 2016-08-24 | 苏州云轩医药科技有限公司 | Pyridine-heterocyclic compound with activity of hedgehog path antagonist and application thereof |
| JP2016516671A (en) | 2013-02-28 | 2016-06-09 | シグナル ファーマシューティカルズ,エルエルシー | Treatment of cancer with TOR kinase inhibitors |
| US9187454B2 (en) | 2013-03-13 | 2015-11-17 | Boston Biomedical, Inc. | Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof |
| BR112015021549A2 (en) | 2013-03-13 | 2017-07-18 | Abbvie Inc | pyridine kinase cdk9 inhibitors |
| TW201446768A (en) | 2013-03-15 | 2014-12-16 | Biogen Idec Inc | S1P and/or ATX modulating agents |
| EP2978425B1 (en) | 2013-03-27 | 2017-09-27 | Merck Sharp & Dohme Corp. | Factor xia inhibitors |
| NZ754629A (en) | 2013-06-21 | 2021-07-30 | Zenith Epigenetics Ltd | Novel bicyclic bromodomain inhibitors |
| WO2015200677A2 (en) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| CN106467538B (en) | 2015-08-14 | 2019-03-05 | 沈阳中化农药化工研发有限公司 | A kind of substituted tetrahydro isoquinoline compound and purposes |
| MX2021001186A (en) | 2015-11-20 | 2022-10-11 | Forma Therapeutics Inc | Purinones as ubiquitin-specific protease 1 inhibitors. |
| CN107629071B (en) | 2016-07-19 | 2019-12-27 | 上海勋和医药科技有限公司 | Substituted 2,4- (1H,3H) pyrimidinedione as PARP inhibitor and application thereof |
| CN107629057B (en) | 2016-07-19 | 2020-03-27 | 上海勋和医药科技有限公司 | BET protein inhibitor and application thereof |
| US20180177784A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| AU2019405925B2 (en) | 2018-12-20 | 2025-07-03 | KSQ Therapeutics, Inc. | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors |
| WO2020139988A1 (en) | 2018-12-28 | 2020-07-02 | Forma Therapeutics, Inc. | Compositions for inhibiting ubiquitin specific protease 1 |
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
| SG11201804934PA (en) | Novel Compounds | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
| SG11201909278SA (en) | Fungicidal oxadiazoles | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201805709RA (en) | Anti-pro/latent myostatin antibodies and methods of use thereof | |
| SG11201804373VA (en) | Compositions and methods for immunooncology | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201804443UA (en) | Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201804589TA (en) | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | |
| SG11201807540UA (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201900665VA (en) | Cannabis composition | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201808221QA (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof |